Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The Parsortix system was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer
ReNeuron Group PLC is at the forefront of stem cell science
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Summit Therapeutics' potential breakthrough targets C.difficile
LTG is paying an initial US$12mln for Breezy HR, while a three-year earn-out with tough targets could push up the value of the deal
The presentation provided a drill-down in the results from the company’s REVIVE study
Its application for a mining concession in Sweden should be adjudicated before the summer
The treatment has been developed to tackle a gram-negative bacteria that is becoming resistant to current drugs
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.